Hong Kong Exchanges and Clearing Limited

FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation

Form Serial Number:

DA20220630E00023

1. Date of relevant event:

29/06/2022
(dd/mm/yyyy)

2. Date when director became aware of the relevant event/ interest in the shares (if later):

(dd/mm/yyyy)

3. Stock code:

02289

4. Name of listed corporation:

Charmacy Pharmaceutical Co., Ltd. - Domestic Shares

5. Class of shares:

Domestic Shares

6. Number of issued shares in class:

7. Name of director (English) as printed on HKID Card/Passport:

(Surname)	Yao
(Other names)	Chuanglong

10. Name of director (Chinese):

姚創龍

11. Chinese Character Code as printed on HKID Card:

24. Details of relevant event:

Brief description of relevant event

Capacity in which shares were/are held

Number of shares bought/sold or involved

Currency of transaction

On Exchange

Off Exchange

Before relevant event

After relevant event

Highest price (per share)

Average price (per share)

Average consideration (per share)

Consideration code

Long position

1213	The number of shares in which you are interested has reduced because: any other event (you must briefly describe the relevant event in the Supplementary Information box)

2101	Beneficial owner

44,250,000

Short position

25. Total shares in listed corporation immediately before the relevant event:

	Total number of shares	Percentage figure (%)
Long position	44,250,000	55.31

26. Total shares in listed corporation immediately after the relevant event:

	Total number of shares	Percentage figure (%)
Long position	0	0.00

27. Capacity in which interests disclosed in Box 26 are held:

Code describing capacity	Number of shares

28. Further information in derivative interests in listed corporation :

Derivatives code

Exercise period (dd/mm/yyyy)

Consideration - if derivatives granted by listed corporation

Number of shares

		Begins	Ends	Currency	Price for grant	Currency	Exercise price	Currency	Price on assignment

29. Further information in relation to interests of children under 18 and/or spouse:

Child/Spouse	Name of child/spouse	Number of shares

30. Further information in relation to interests of corporations controlled by Director:

Name of controlled corporation	Address and place of incorporation	Name of controlling person	% control	Direct interest (Y/N)	Number of shares

31. Further information in relation to interests held by Director jointly with another person:

Name of joint shareholder	Address	Number of shares

32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:

Names of Trust	Address	Status code	Number of shares

33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):

Names of other parties	Address	Number of shares

Total number of shares in which a director is interested under sections 317 and 318

34. Supplementary information:

创美药业股份有限公司（「本公司」）于2022年6月6日获中国证券监督管理委员会正式批准（按本公司日期为2022年6月6日之公告所披露）及于2022年6月14日获香港联合交易所有限公司（「联交所」）批准（按本公司日期为2022年6月15日之公告所披露），最高80,000,000股本公司非上市内资股转换为本公司H股并于联交所上市。按本公司日期为2022年6月29日之公告所披露，有关转换已于2022年6月29日完成。

35. Log/Serial Number of the previous form:

36. Number of concert party document(s) under section 317 attached/uploaded:

Date of filing this Form 3A:

30/06/2022
(dd/mm/yyyy)